首页> 美国卫生研究院文献>Journal of Ophthalmology >Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
【2h】

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture

机译:玻璃体内贝伐单抗(阿瓦斯汀)治疗糖尿病性视网膜病变:2010 GLADAOF演讲

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.
机译:本文证明了玻璃体内贝伐单抗(IVB)对糖尿病视网膜病变(DR)的多种益处,包括随访24个月的糖尿病性黄斑水肿(DME)和增生性糖尿病视网膜病变(PDR)。这是一项回顾性多中心介入性比较病例系列研究,一系列玻璃体内注射1.25或2.5 mg贝伐单抗用于DME,PDR而无牵引性视网膜脱离(TRD),以及玻璃体内注射1.25或2.5μmg后经历TRD的发展或进展的患者玻璃体切除术前贝伐单抗治疗PDR。结果表明,IVB注射可能对弥漫性DME中的黄斑厚度和视敏度(VA)产生有益影响。因此,将来这种新疗法可以补充DME中的聚焦/栅格激光光凝。在PDR中,此新选项可能是全视网膜光凝的辅助剂,因此可以应用更多选择性治疗。最后,IVB用作玻璃体切除术的佐剂后,PDR中的TRD可能发生或发展。手术应在IVB后4天进行。大多数患者的糖尿病控制不佳,伴有HbA1c升高,胰岛素给药,全视网膜光凝难治性PDR,以及IVB和玻璃体切除术之间的时间较长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号